The Effect of Nano-curcumin Supplementation in Acute Pancreatitis
Study Details
Study Description
Brief Summary
This study aimed to investigate the effect of Nano-curcumin supplementation on clinical symptoms and signs, length of hospital stay and inflammation level in moderate acute pancreatitis. 42 eligible patients with moderate acute pancreatitis will randomly assign to consume two soft gels each containing 40 mg of Nano-curcumin or placebo (control group) every morning and evening for two weeks. Both groups will also receive the standard medical treatment in hospital. Patients' blood samples will be taken before and after the intervention to determine complete blood count (CBC), kidney and liver function, blood sugar, electrolytes and C-reactive protein (CRP). Clinical signs during the hospitalization period will be recorded and the two groups will also be compared in terms of local complications and length of hospital stay.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Dietary intake of patients will be examined by two non-consecutive 24-hour food recalls at the beginning and end of the study. Patient's weight (kg) and Body Mass Index (BMI) will also be measured.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Nano-curcumin 80mg of Nano-curcumin daily |
Dietary Supplement: Nano-curcumin
Nano-curcumin soft gels
|
| Placebo Comparator: Placebo Placebo |
Drug: Placebo
Placebo
|
Outcome Measures
Primary Outcome Measures
- Length of hospital stay [through study completion, an average of 2 weeks]
Admission days in hospital
- Serum CRP level [2 weeks]
serum C-reactive protein level
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with a clinical diagnosis of moderate acute pancreatitis (specifically, a history of acute abdominal pain associated with a greater than threefold elevation of the serum amylase and/or computed tomographic evidence of acute pancreatitis) presenting within 72 hours of onset of pain
-
Age range of 18-75
-
having the ability to intake soft gels orally
-
lack of Pregnancy or breastfeeding
-
lack of any history of allergy to Curcumin
-
Patients with no acute exacerbation of chronic pancreatitis
-
lack of prior antioxidant therapy
-
lack of severe co-morbid illness (liver disease including cirrhosis and hepatitis, Renal failure (Cl Cr <30))
-
lack of active gastrointestinal ulcers
-
not to take anticoagulants such as heparin, Clopidogrel, Dipyridamole, Warfarin and Ticlopidine
Exclusion Criteria:
-
The patient's unwillingness to continue cooperating
-
Patients who have not consumed more than 20% of soft gels
-
The diagnosis of the treating physician based on the termination of the patient's participation in the study
-
Incidence of side effects due to supplementation in the patient
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National Nutrition and Food Technology Research Institute | Tehran | Iran, Islamic Republic of |
Sponsors and Collaborators
- National Nutrition and Food Technology Institute
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 28664